Table 2.
Summary Statistics for Serum Concentrations of 10 Biomarkers Over 14 Weeks.
| Biomarker | Baseline (N = 27), Mean (SD) | Week 1 (n = 26), Mean (SD) | Week 2 (n = 24), Mean (SD) | Week 4 (n = 23), Mean (SD) | Week 8 (n = 22), Mean (SD) | Week 14 (n = 24), Mean (SD) |
|---|---|---|---|---|---|---|
| IL-6 (pg/mL) | 4.04 (6.81) | 3.54 (5.45) | 2.58 (2.74) | 2.58 (2.61) | 7.21 (21.52) | 3.16 (3.29) |
| IL-8 (pg/mL) | 1.14 (0.13) | 1.13 (0.10) | 1.15 (0.13) | 1.14 (0.12) | 1.14 (0.13) | 1.09 (0.20) |
| IL-10 (pg/mL) | 3.81 (3.78) | 3.73 (3.34) | 3.76 (2.79) | 3.62 (3.01) | 11.35 (32.60) | 6.71 (10.76) |
| TNF-α (pg/mL) | 1.93 (1.12) | 1.99 (1.31) | 2.60 (2.80) | 2.43 (2.97) | 3.26 (3.44) | 2.08 (1.33) |
| VEGF (pg/mL) | 72.51 (43.91) | 73.19 (43.63) | 87.73 (75.73) | 95.89 (86.48) | 91.28 (59.30) | 92.18 (81.98) |
| IGF-1 (pg/mL) | 4839.67 (3241.82) | 4811.01 (3423.22) | 4928.70 (3517.36) | 4822.97 (3138.45) | 4763.74 (3219.96) | 5565.86 (4338.65) |
| NGF (pg/mL) | 1.08 (0.79) | 1.13 (0.86) | 1.54 (2.29) | 1.98 (4.09) | 1.18 (1.01) | 0.98 (0.65) |
| BDNF (pg/mL) | 952.60 (873.50) | 756.90 (626.98) | 926.83 (818.60) | 1023.37 (947.13) | 717.19 (513.33) | 705.10 (579.02) |
| NT-3 (pg/mL) | 30.85 (111.40) | 31.58 (116.22) | 29.37 (107.57) | 30.22 (102.75) | 36.42 (127.93) | 24.77 (85.28) |
| β-EP (ng/mL) | 1.14 (0.13) | 1.13 (0.10) | 1.15 (0.13) | 1.14 (0.12) | 1.14 (0.13) | 1.09 (0.20) |
| IL-17a (pg/mL) | N/Aa | N/Aa | N/Aa | N/Aa | N/Aa | N/Aa |
| MIP-1α (pg/mL) | 15.4 (12.9) | 18.4 (16.0) | Not tested | Not tested | 39.2 (45.0) | 14.7 (12.3) |
Abbreviations: SD, standard deviation; IL, interleukin; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; IGF-1, insulin-like growth factor-1; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin-3; β-EP, β-endorphin; MIP-1α, macrophage inflammatory protein-1α; N/A, not applicable.
a
All but one patient had IL-17a below detectable levels.